Transfusion-associated graft versus host disease

Transfusion-Associated Graft Versus Host Disease (TA-GVHD) is a rare but often fatal complication that can occur after a blood transfusion. This condition arises when the immune cells present in the transfused blood recognize the recipient's body as foreign and initiate an immune response against the host's tissues. TA-GVHD is characterized by fever, rash, diarrhea, and liver dysfunction, and can lead to severe damage to the skin, liver, gastrointestinal tract, and bone marrow.

Etiology

TA-GVHD occurs when immunocompetent donor T lymphocytes are transfused into a recipient, who is unable to mount an effective immune response against these cells. This inability may be due to immunodeficiency in the recipient, or because the donor and recipient share certain Human Leukocyte Antigen (HLA) haplotypes, making the donor's lymphocytes less recognizable as foreign. This condition is more commonly associated with transfusions from blood relatives or HLA-matched platelet transfusions.

Pathophysiology

The pathogenesis of TA-GVHD involves the engraftment and proliferation of donor T lymphocytes in the recipient's body. These donor T cells then recognize the host's cells as foreign and initiate an immune response. This leads to widespread tissue damage, particularly affecting the skin, liver, gastrointestinal tract, and the hematopoietic system.

Clinical Features

The symptoms of TA-GVHD typically develop within 1 to 6 weeks post-transfusion. Common signs and symptoms include:

• Fever
• Skin rash, often starting on the palms and soles and spreading centrally
• Diarrhea
• Hepatic dysfunction
• Pancytopenia due to bone marrow involvement

Diagnosis

Diagnosis of TA-GVHD is based on clinical presentation, history of recent transfusion, and laboratory findings. Biopsy of affected tissues, such as skin or liver, showing characteristic histological features of GVHD can confirm the diagnosis. Additionally, molecular techniques to demonstrate the presence of donor lymphocytes in the recipient's circulation can be supportive.

Prevention

Prevention of TA-GVHD is primarily focused on irradiation of blood products before transfusion. This process inactivates the lymphocytes present in the donated blood, preventing them from proliferating in the recipient. Irradiation is recommended for blood transfusions in high-risk patients, including those with congenital immunodeficiencies, recipients of HLA-matched products, and patients receiving blood from family members.

Treatment

The treatment of TA-GVHD is challenging, and there is no established therapy. Management is mainly supportive, focusing on treating the symptoms and preventing infections. High-dose corticosteroids and other immunosuppressive agents have been used, but their effectiveness is limited. The prognosis of TA-GVHD is poor, with a high mortality rate.

Conclusion

Transfusion-Associated Graft Versus Host Disease is a severe complication of blood transfusion, characterized by an immune-mediated attack on the host by donor T cells. Prevention through irradiation of blood products is the most effective strategy, as treatment options are limited and the condition is often fatal.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian